Compare Agilent Technologies Inc (A) vs Chubb Ltd (CB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Chubb Ltd — how do they compare? Agilent Technologies Inc trades at $128.94 (market cap $37.04B), while Chubb Ltd trades at $356.48 (market cap $139.36B). The key difference: Chubb Ltd is far larger — about 3.8× Agilent Technologies Inc's market cap, and Chubb Ltd pays the higher dividend (1.14%). Which is the better fit depends on your goals.
| A | CB | |
|---|---|---|
Market Cap | $37.04B | $139.36B |
Sector | Health | Financials |
52-Week High | $157.20 | $361.17 |
52-Week Low | $110.24 | $265.99 |
Enterprise Value | $38.59B | $160.41B |
Dividend Yield | 0.78% | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Chubb (CB) trades at $359.30, down 0.52% on the day but near its 52-week high, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $59.78B in 2025 to projected $61.2B in 2026, and a net income margin of 18.46%. Recent news highlights premium growth and disciplined underwriting as key strengths.
Outlook remains positive with analyst consensus favoring Buy ratings (52.38%) and a price target of $341.90, though risks include catastrophe losses and softer commercial pricing. The stock's valuation at P/E 12.61 offers value, but investors should monitor Q2 2026 earnings due July 22, 2026, for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →
